WO2008045817A2 - Compositions permettant de réduire les symptômes de sevrage de nicotine et/ou l'usage du tabac - Google Patents

Compositions permettant de réduire les symptômes de sevrage de nicotine et/ou l'usage du tabac Download PDF

Info

Publication number
WO2008045817A2
WO2008045817A2 PCT/US2007/080678 US2007080678W WO2008045817A2 WO 2008045817 A2 WO2008045817 A2 WO 2008045817A2 US 2007080678 W US2007080678 W US 2007080678W WO 2008045817 A2 WO2008045817 A2 WO 2008045817A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
nicotine
individual
dextromethorphan
cotinine
Prior art date
Application number
PCT/US2007/080678
Other languages
English (en)
Other versions
WO2008045817A3 (fr
WO2008045817A8 (fr
Inventor
Shing Yue Chan
Charlotte A. Lemmonds
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Priority to US12/444,208 priority Critical patent/US20100040679A1/en
Priority to BRPI0719260-6A2A priority patent/BRPI0719260A2/pt
Priority to JP2009532516A priority patent/JP2010505960A/ja
Priority to EP07843960A priority patent/EP2086541A4/fr
Priority to AU2007307859A priority patent/AU2007307859A1/en
Priority to CA002676133A priority patent/CA2676133A1/fr
Priority to EA200970369A priority patent/EA200970369A1/ru
Priority to MX2009003845A priority patent/MX2009003845A/es
Publication of WO2008045817A2 publication Critical patent/WO2008045817A2/fr
Publication of WO2008045817A3 publication Critical patent/WO2008045817A3/fr
Publication of WO2008045817A8 publication Critical patent/WO2008045817A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to compositions useful for treating nicotine dependence comprising a combination of an 0 3 ⁇ 4 nicotinic receptor antagonist and a nicotine metabolite. More particularly, the invention relates to compositions comprising: dextromethorphan, dextrorphan or pharmaceutically acceptable salts thereof; and cotinine or pharmaceutical acceptable salts thereof. The invention also relates to methods of using such compositions for reducing nicotine withdrawal symptoms and reducing tobacco usage.
  • Nicotine addiction is a complex process which includes pharmacological, psychological and social factors.
  • One pharmacological mechanism of nicotine addiction is the activation of the nicotinic acetylcholine receptor causing the release of dopamine in the mesolimbic pathway of the brain.
  • the release of dopamine is strongly associated to addiction, the release of other neurotransmitters (such as acetylcholine, norepineneprhine, serotonin, glutamate and others) may contribute to nicotine addiction as well.
  • Nicotine withdrawal symptoms may arise in several ways. For instance, studies have shown that following a quit attempt, smokers report moderate levels of steady nicotine craving throughout the day. This could lead to relapse and a return to tobacco usage for those attempting to quit. In addition to steady cravings, smokers may also experience episodic, or acute, cravings. These acute cravings may be provoked by a number of stimuli, such as exposure to smoking related cues, seeing smoking paraphernalia or others engaged in smoking, or inhaling second hand smoke. Such episodic cravings may also lead to relapse if proper coping measures are not employed.
  • NRT nicotine replacement therapy
  • dextrorphan Dextromethorphan and its active metabolite, dextrorphan are also known antagonists of the N-methyl D-apartate (NMDA) receptor. See WO 00/16762 to Caruso.
  • NMDA N-methyl D-apartate
  • dextromethorphan and dextrorphan have been shown to act as ⁇ 3 ⁇ 4 nicotinic receptor antagonists and, thus, block the neural nicotinic receptors in the central and autonomic nervous system.
  • US 2002/0103109 to Glick It has been speculated that each antagonistic activity may contribute to the usefulness of dextromethorphan and dextrorphan for reducing nicotine, as well as other substance dependence. See Caruso and Glick.
  • Glick et al. relates to methods and compositions for treating addiction disorders by administration of a first and a different second ⁇ 3 ⁇ 4 nicotinic receptor antagonist.
  • Caruso relates to methods for reducing nicotine dependence by administering at least one nicotine-dependency reducing agent selected from the group consisting of dextromethorphan, dextrorphan and pharmaceutically acceptable salts thereof.
  • US 2005/0100902 to Grattan relates to vaccines for treating nicotine addiction comprising a metabolite of nicotine, which is used for immunotherapy of nicotine addiction.
  • US 2006/0112965 to Whalen relates to a chewing tobacco substitute which comprises a non-tobacco leaf component, an alkaline component and a nicotine compound such as nicotine polacrilex or cotinine.
  • a ci3 ⁇ 4 nicotinic receptor antagonist such as dextromethorphan
  • a metabolite of nicotine such as cotinine
  • the present invention relates to combination therapies comprising ⁇ 3 ⁇ 4 nicotinic receptor antagonists and metabolites of nicotine for treating nicotine addiction. More particularly, the present invention relates to compositions comprising dextromethorphan, dextrorphan or pharmaceutically acceptable salts thereof; and cotinine or pharmaceutically acceptable salts thereof. The present invention also relates to methods of reducing nicotine withdrawal symptoms and tobacco usage by administering compositions comprising dextromethorphan, dextrorphan or pharmaceutically acceptable salts thereof, and cotinine or pharmaceutically acceptable salts thereof.
  • the present invention relates to compositions suitable for reducing nicotine withdrawal symptoms or tobacco usage which comprise an ⁇ 3 ⁇ 4 nicotinic receptor antagonist and a nicotine metabolite.
  • the ⁇ 3 ⁇ 4 nicotinic receptor antagonist is selected from dextromethorphan, dextrorphan or their pharmaceutically acceptable salts.
  • the metabolite of nicotine is cotinine or pharmaceutically acceptable salts thereof.
  • the composition comprises low doses of dextromethorphan, dextrorphan or a pharmaceutically acceptable salt thereof and cotinine or pharmaceutically acceptable salts thereof.
  • the present invention also relates to methods of reducing nicotine withdrawal symptoms and/or reducing tobacco usage by administration of the compositions described herein.
  • Figure 1 depicts overall mecamylamine-precipitated nicotine abstinence signs over 30 minutes in subjects pretreated subcutaneously with 1 mg/kg dextromethorphan, 1 mg/kg cotinine, a combination of dextromethorphan and cotinine each as 1 mg/kg, and saline alone.
  • Figure 2 depicts individual categories of mecamylamine-precipitated nicotine abstinence signs over 30 minutes in subjects pretreated subcutaneously with 1 mg/kg dextromethorphan, 1 mg/kg cotinine, a combination of dextromethorphan and cotinine each as 1 mg/kg, and saline alone.
  • tobacco usage means the usage of tobacco in any form by an individual, including smoking, such as cigars, cigarettes, and pipe tobacco, and using smokeless tobacco, such as snuff tobacco, spit tobacco and chewing tobacco.
  • tobacco withdrawal symptoms includes, but are not limited to, nicotine cravings, difficulty in sleeping, irritability, anxiety, restlessness, difficulty with concentration, increased appetite, weight gain and depressed mood.
  • An 033 4 nicotinic receptor antagonist as used herein means a compound that directly or indirectly blocks or otherwise reduces the activity of an ⁇ 3 ⁇ 4 nicotinic receptor.
  • ⁇ 3 ⁇ 4 nicotinic receptor antagonists that are suitable for use in the present invention include, but are not limited to, mecamylamine, 18- methoxycoronaridine, bupropion, dextromethorphan, dextrorphan, and pharmaceutically acceptable salts thereof.
  • the ci 3 ⁇ 4 nicotinic receptor antagonist is selected from dextromethorphan, dextrorphan, and pharmaceutically acceptable salts thereof.
  • the C ⁇ 4 nicotinic receptor antagonist is selected from dextromethorphan and pharmaceutically acceptable salts thereof.
  • the term “dextromethorphan” refers to dextromethorphan or any of its pharmaceutically acceptable salts.
  • the term “dextrorphan” refers to dextrorphan or any of its pharmaceutically acceptable salts.
  • dextrorphan Dextromethorphan and its active metabolite, dextrorphan are known antagonists of the N-methyl D-apartate (NMDA) receptor.
  • NMDA N-methyl D-apartate
  • dextromethorphan and dextrorphan have been shown to block the neural nicotinic receptors in the central and autonomic nervous system, such as the ⁇ 3 ⁇ 4 nicotinic receptor antagonists. It has been speculated that both mechanisms may contribute to the usefulness of dextromethorphan and dextrorphan for reducing nicotine dependence.
  • the dose range of dextromethorphan or dextorphan is from about 0.01 mg/kg to about 10 mg/kg of an individual's body weight per dose. In one embodiment the dose range of dextromethorphan or dextorphan is from about 0.01 mg/kg to about 1.6 mg/kg of an individual's body weight per dose. In yet another embodiment the dose range of dextromethorphan or dextorphan is from about 0.02 mg/kg to about 1.0 mg/kg of an individual's body weight per dose.
  • Metabolites of nicotine are generally derivatives of nicotine that are produced by the human body as a result of consumption, e.g., smoking, chewing, inhalation, or exposure, to a nicotine-containing material or as a result of environmental exposure to nicotine.
  • the term "nicotine metabolite”, as used herein, is intended to refer to any pharmacologically acceptable metabolite of nicotine which exhibits pharmacotherapeutic properties similar to nicotine.
  • Such metabolites are known in the art, and include cotinine, norcotinine, nornicotine, nicotine 1 '-N-oxide, cotinine N-oxide, cotinine glucuronide, nicotine glucuronide, trans-3'-hydroxycotinine and 5- hydroxycotinine or pharmaceutically acceptable salts thereof.
  • the metabolite of nicotine is cotinine or a pharmaceutically acceptable salt thereof.
  • cotinine refers to cotinine or any of its pharmaceutically acceptable salts. Cotinine has been shown to be a major metabolite of nicotine and a study by Benowitz (Clin. Pharmacol. Ther. (1983) 34(5), 604-61 1 ) estimated that 86% of systemically absorbed nicotine is metabolized to cotinine in humans. Cotinine has also been shown (Dwoskin et al, The Journal of Pharmacology and Experimental Therapeutics (1999), 288(2), 905-911 ) to be the most abundant metabolite in rat brain after peripheral nicotine administration. Studies also suggest that cotinine has psychological activity that can antagonize the effects of nicotine in vivo in humans. ⁇ Hatsukami et al. Psychopharmacology (1998) 135: 141-150).
  • the nicotine metabolite is cotinine.
  • Cotinine is shown by the following structure:
  • the dose range of cotinine is from about 0.01 mg/kg to about 100 mg/kg of an individual's body weight per dose. In one embodiment the dose range of cotinine is from about 0.1 mg/kg to about 10 mg/kg of an individual's body weight per dose. In yet another embodiment, the dose range of cotinine is from about 0.2 mg/kg to about 3 mg/kg of an individual's body weight per dose
  • dextromethorphan or dextorphan and cotinine are both present in the compositions of the present invention
  • low doses of dextromethorphan or dextorphan and cotinine may provide relief of nicotine withdrawal symptoms to an individual in need thereof.
  • low levels of dextromethorphan or dextorphan and cotinine which provide little or no nicotine withdrawal symptom relief when provided individually, provide surprisingly higher levels of such relief when combined in the compositions of the present invention.
  • the dose range of dextromethorphan or dextorphan is from about 0.02 mg/kg to about 1 mg/kg of an individual's body weight per dose and the dose range of cotinine is from about 0.2 mg/kg to about 1 mg/kg of an individual's body weight per dose.
  • the subjects were 30 male Sprague- Dawley rats, weighing between 282 - 372 grams each. All subjects were implanted subcutaneously with an Alza 2ML1 osmotic minipump under aseptic conditions and halothane anesthesia.
  • the cotinine and dextromethorphan doses were selected on the basis of a previous study as having only minimal effects in reducing mecamylamine-precipitated nicotine withdrawal syndrome. These low doses were intended to prevent any ceiling effect which may have masked the benefit of adding a second medication.
  • the injection volumes in every case were 1 mg/kg.
  • each rat was challenged by 1 mg/kg subcutaneous of the nicotinic antagonist mecamylamine HCI. Each rat was then observed under blind conditions over a thirty-minute interval for precipitated nicotine abstinence signs, utilizing a standard checklist.
  • Figure 1 depicts overall mecamylamine-precipitated nicotine abstinence signs cumulated across all categories.
  • the combined-treatment group (cotinine plus dextromethorphan) had fewer signs than any other group.
  • Figure 2 depicts occurrences of individual categories of nicotine abstinence signs. In every case, the combined-treatment group had the fewest signs, except for Miscellaneous Less-Frequent Signs, where it was tied for lowest with the group receiving cotinine alone.
  • compositions of the present invention are contemplated, i.e., transdermal, oral, nasal, rectal, intravenous, intramuscular, or subcutaneous.
  • transdermal patch can be configured to release an equivalent effective dose of dextromethorphan and cotinine to those described, over a period of time.
  • sustained release transdermal patches can be formulated using techniques known in the art.
  • compositions of the present invention are orally administered with absorption occurring either within the alimentary canal or via the oral or buccal mucosa of the oral cavity.
  • Suitable oral dosage forms for compositions of the present invention include, but are not limited to; tablets, such as compressed tablets which may be coated or uncoated; caplets; hard gelatin capsules; dispersible powders; lozenges, such as hard boiled or compressed lozenges; orally dissolving strips; chewable gums; suspensions; syrups; and elixirs.
  • the composition is provided in a tablet or hard gelatin capsule dosage form.
  • the dextromethorphan and cotinine may be mixed with an inert solid diluent, filler or bulking agent, such as, but not limited to lactose, sucralose, sucrose, glucose, fructose, trehalose, silica, dextrates, xylitol, sorbitol, mannitol, cellulose derivatives, calcium carbonate, sodium carbonate, calcium phosphate, kaolin, talc or mixtures thereof.
  • Diluents, fillers and or bulking agents may comprise from about 25% to about 95% by weight of the total composition.
  • diluents, fillers and/or bulking agents may comprise from about 50% to about 90% by weight of the total dosage form.
  • Lubricants/glidants may be incorporated into such tablet or capsule dosage forms.
  • Lubricants and glidants suitable for use include, but are not limited to, talc, corn starch, stearic acid, calcium stearate, polyethylene glycol, colloidal silicon dioxide, sodium stearyl fumarate, magnesium stearate vegetable and mineral oils and mixtures thereof.
  • the lubricant is magnesium stearate.
  • the lubricant may be present in an amount up to about 10% by weight of the total composition. In one embodiment the lubricant may be present in an amount up to about 5% by weight of the total dosage form.
  • Binding agents may also optionally be added to the dosage forms comprising the compositions of the present invention. Suitable binding agents include, but are not limited to, starch, gelatin, acacia, povidone or carbopol, or mixtures thereof. Where binding agents are incorporated into the dosage forms, they are generally present in an amount up to about 25% of the weight of the total dosage form. In one embodiment, binding agents are present up to about 10% by weight of the total dosage form.
  • Disintegrants may also optionally be added to the dosage forms comprising the compositions of the present invention. Suitable disintegrants include, but are not limited to, starch, alginic acid, sodium starch glycolate, or mixtures thereof. Where disintegrants are incorporated into the dosage form, they are generally present in an amount up to about 25% of the weight of the total dosage form. In one embodiment, disintegrants are present up to about 10% by weight of the total dosage form.
  • compositions of the present invention including, but not limited to: flavorants, such as peppermint, spearmint, menthol, citrus, fruit flavors, vanilla, cinnamon, chocolate, coffee or tobacco flavors; colorants, such as pigments, natural food colors and dyes; sweeteners, such as the high intensity sweeteners acesulfame-K and aspartame; antioxidants/preservatives, such as sodium benzoate, butyl-hydroxy toluene and tocopherol and its salts; vitamins, such as Vitamin C or E; taste masking agents; plasticizers; and emulsifiers/surfactants.
  • flavorants such as peppermint, spearmint, menthol, citrus, fruit flavors, vanilla, cinnamon, chocolate, coffee or tobacco flavors
  • colorants such as pigments, natural food colors and dyes
  • sweeteners such as the high intensity sweeteners acesulfame-K and aspartame
  • antioxidants/preservatives such as sodium benzoate, butyl-hydroxy toluene
  • compositions of the present invention are useful as a tobacco replacement, and as a means to reduce or stop tobacco use.
  • the compositions may be used as a total or partial replacement of tobacco, and may be used concurrently with tobacco as part of a planned tobacco reduction program, e.g., while reducing tobacco usage prior to outright quitting tobacco usage.
  • the present invention also relates to methods of reducing tobacco usage, comprising administering a composition of the present invention to a person in need thereof.
  • the present invention also relates to a method of reducing nicotine withdrawal symptoms comprising administering the compositions of the present invention to a person in need of such relief.
  • Need is intended to include a person's desire to reduce tobacco usage or nicotine withdrawal symptoms, respectively.
  • Reducing nicotine withdrawal symptoms or tobacco usage includes eliminating nicotine withdrawal symptoms or tobacco usage.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des compositions utilisables pour traiter un individu ayant une dépendance à la nicotine, lesdites compositions comprenant la combinaison d'un antagoniste du récepteur nicotinique 03^4 et un métabolite de la nicotine. L'invention concerne plus particulièrement des compositions comprenant du dextrométhorphan, du dextrorphan ou un sel pharmaceutiquement acceptable de ceux-ci et comprenant en outre de la cotinine ou un sel pharmaceutiquement acceptable de celle-ci. L'invention concerne également des procédés permettant de soulager les symptômes de sevrage de nicotine et/ou de réduire l'usage du tabac par l'administration de ces compositions.
PCT/US2007/080678 2006-10-09 2007-10-08 Compositions permettant de réduire les symptômes de sevrage de nicotine et/ou l'usage du tabac WO2008045817A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US12/444,208 US20100040679A1 (en) 2006-10-09 2007-10-08 Compositions for Reducing Nicotine Withdrawal Symptoms and/or Tobacco Usage
BRPI0719260-6A2A BRPI0719260A2 (pt) 2006-10-09 2007-10-08 Composições para a redução de sintomas de supressão de nicotina e/ou do uso de tabaco.
JP2009532516A JP2010505960A (ja) 2006-10-09 2007-10-08 ニコチン禁断症状および／またはタバコ使用の軽減用組成物
EP07843960A EP2086541A4 (fr) 2006-10-09 2007-10-08 Compositions permettant de réduire les symptômes de sevrage de nicotine et/ou l'usage du tabac
AU2007307859A AU2007307859A1 (en) 2006-10-09 2007-10-08 Compositions for reducing nicotine withdrawal symptoms and/or tobacco usage
CA002676133A CA2676133A1 (fr) 2006-10-09 2007-10-08 Compositions permettant de reduire les symptomes de sevrage de nicotine et/ou l'usage du tabac
EA200970369A EA200970369A1 (ru) 2006-10-09 2007-10-08 Композиции для снижения симптомов никотиновой абстиненции и/или отказа от употребления табака
MX2009003845A MX2009003845A (es) 2006-10-09 2007-10-08 Composiciones para reducir los sintomas de abstinencia de nicotina y/o el uso del tabaco.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82868206P 2006-10-09 2006-10-09
US60/828,682 2006-10-09

Publications (3)

Publication Number Publication Date
WO2008045817A2 true WO2008045817A2 (fr) 2008-04-17
WO2008045817A3 WO2008045817A3 (fr) 2008-10-09
WO2008045817A8 WO2008045817A8 (fr) 2009-05-07

Family

ID=39283542

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/080678 WO2008045817A2 (fr) 2006-10-09 2007-10-08 Compositions permettant de réduire les symptômes de sevrage de nicotine et/ou l'usage du tabac

Country Status (12)

Country Link
US (1) US20100040679A1 (fr)
EP (1) EP2086541A4 (fr)
JP (1) JP2010505960A (fr)
CN (1) CN101522193A (fr)
AR (1) AR063148A1 (fr)
AU (1) AU2007307859A1 (fr)
BR (1) BRPI0719260A2 (fr)
CA (1) CA2676133A1 (fr)
CL (1) CL2007002903A1 (fr)
EA (1) EA200970369A1 (fr)
MX (1) MX2009003845A (fr)
WO (1) WO2008045817A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103776928A (zh) * 2014-01-13 2014-05-07 红云红河烟草(集团)有限责任公司 一种检测尿液中3-羟基可替宁的方法
EP2830601A4 (fr) * 2012-03-27 2015-09-23 Albany Medical College Blocage de la reprise de l'usage de drogues induite par un signal

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110274628A1 (en) * 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
US9185931B2 (en) * 2013-05-13 2015-11-17 Altria Client Services Inc. Oral product
US11298352B2 (en) 2013-11-05 2022-04-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11969421B2 (en) 2013-11-05 2024-04-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10966941B2 (en) 2013-11-05 2021-04-06 Antecip Bioventures Ii Llp Bupropion as a modulator of drug activity
US11576909B2 (en) 2013-11-05 2023-02-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11065248B2 (en) 2013-11-05 2021-07-20 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11433067B2 (en) 2013-11-05 2022-09-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11419867B2 (en) 2013-11-05 2022-08-23 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10966942B2 (en) 2019-01-07 2021-04-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10874665B2 (en) 2013-11-05 2020-12-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11090300B2 (en) 2013-11-05 2021-08-17 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11058648B2 (en) 2013-11-05 2021-07-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10772850B2 (en) 2013-11-05 2020-09-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11617747B2 (en) 2013-11-05 2023-04-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11617728B2 (en) 2013-11-05 2023-04-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11596627B2 (en) 2013-11-05 2023-03-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US20220233470A1 (en) 2013-11-05 2022-07-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10898453B2 (en) 2013-11-05 2021-01-26 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11096937B2 (en) 2013-11-05 2021-08-24 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10780064B2 (en) 2019-01-07 2020-09-22 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11285118B2 (en) 2013-11-05 2022-03-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11541048B2 (en) 2013-11-05 2023-01-03 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10786469B2 (en) 2013-11-05 2020-09-29 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11229640B2 (en) 2013-11-05 2022-01-25 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US11273133B2 (en) 2013-11-05 2022-03-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11234946B2 (en) 2013-11-05 2022-02-01 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11207281B2 (en) 2013-11-05 2021-12-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10940124B2 (en) 2019-01-07 2021-03-09 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10894047B2 (en) 2013-11-05 2021-01-19 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11478468B2 (en) 2013-11-05 2022-10-25 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11129826B2 (en) 2013-11-05 2021-09-28 Axsome Therapeutics, Inc. Bupropion as a modulator of drug activity
US11197839B2 (en) 2013-11-05 2021-12-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11497721B2 (en) 2013-11-05 2022-11-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10105361B2 (en) 2013-11-05 2018-10-23 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US10874664B2 (en) 2013-11-05 2020-12-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11541021B2 (en) 2013-11-05 2023-01-03 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US20200338022A1 (en) 2019-01-07 2020-10-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11273134B2 (en) 2013-11-05 2022-03-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10881657B2 (en) 2013-11-05 2021-01-05 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10874663B2 (en) 2013-11-05 2020-12-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11364233B2 (en) 2013-11-05 2022-06-21 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11020389B2 (en) 2013-11-05 2021-06-01 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11517543B2 (en) 2013-11-05 2022-12-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11426370B2 (en) 2013-11-05 2022-08-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11576877B2 (en) 2013-11-05 2023-02-14 Antecip Bioventures Ii Llc Bupropion as modulator of drug activity
US10933034B2 (en) 2013-11-05 2021-03-02 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US20160324807A1 (en) 2013-11-05 2016-11-10 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11426401B2 (en) 2013-11-05 2022-08-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11253491B2 (en) 2013-11-05 2022-02-22 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11298351B2 (en) 2013-11-05 2022-04-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11185515B2 (en) 2013-11-05 2021-11-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11534414B2 (en) * 2013-11-05 2022-12-27 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10966974B2 (en) 2013-11-05 2021-04-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11141416B2 (en) 2013-11-05 2021-10-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11123344B2 (en) 2013-11-05 2021-09-21 Axsome Therapeutics, Inc. Bupropion as a modulator of drug activity
US9763932B2 (en) 2013-11-05 2017-09-19 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11007189B2 (en) 2013-11-05 2021-05-18 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11590124B2 (en) 2013-11-05 2023-02-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11357744B2 (en) 2013-11-05 2022-06-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11524007B2 (en) 2013-11-05 2022-12-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10799497B2 (en) 2013-11-05 2020-10-13 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US11291665B2 (en) 2013-11-05 2022-04-05 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10813924B2 (en) 2018-03-20 2020-10-27 Antecip Bioventures Ii Llc Bupropion and dextromethorphan for treating nicotine addiction
US10945973B2 (en) 2013-11-05 2021-03-16 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11285146B2 (en) 2013-11-05 2022-03-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11191739B2 (en) 2013-11-05 2021-12-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10080727B2 (en) 2013-11-05 2018-09-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11510918B2 (en) 2013-11-05 2022-11-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11213521B2 (en) 2013-11-05 2022-01-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11147808B2 (en) 2013-11-05 2021-10-19 Antecip Bioventures Ii Llc Method of decreasing the fluctuation index of dextromethorphan
US11382874B2 (en) 2013-11-05 2022-07-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11344544B2 (en) 2013-11-05 2022-05-31 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11123343B2 (en) 2013-11-05 2021-09-21 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11571399B2 (en) 2013-11-05 2023-02-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10864209B2 (en) 2013-11-05 2020-12-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10894046B2 (en) 2013-11-05 2021-01-19 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10688066B2 (en) * 2018-03-20 2020-06-23 Antecip Bioventures Ii Llc Bupropion and dextromethorphan for treating nicotine addiction
US11571417B2 (en) 2013-11-05 2023-02-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11291638B2 (en) 2013-11-05 2022-04-05 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11439636B1 (en) 2013-11-05 2022-09-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11253492B2 (en) 2013-11-05 2022-02-22 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11311534B2 (en) 2013-11-05 2022-04-26 Antecip Bio Ventures Ii Llc Bupropion as a modulator of drug activity
US10980800B2 (en) 2013-11-05 2021-04-20 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10925842B2 (en) 2019-01-07 2021-02-23 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
WO2021199047A1 (fr) * 2020-03-31 2021-10-07 Biomuse Ltd. Bactéries destinées à la prévention et au traitement de lésions pulmonaires induites par la fumée
WO2024006853A1 (fr) 2022-06-30 2024-01-04 Antecip Bioventures Ii Llc Traitement de mauvais métaboliseurs de dextrométhorphane avec une combinaison de bupropion et de dextrométhorphane
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023045A1 (fr) * 1992-05-18 1993-11-25 Pharmaco Behavioral Associates, Inc. Utilisation de la cotinine pour calmer le syndrome de sevrage du tabac
US5869505A (en) * 1993-02-02 1999-02-09 Keenan; Robert M. Nicotine metabolites and nicotine dependence
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
JP2001518520A (ja) * 1997-10-03 2001-10-16 キャリー メディカル コーポレイション ニコチンレセプターアンタゴニストおよび抗抑うつ薬または抗不安薬を含有するニコチン嗜癖を治療する組成物
AU6250299A (en) * 1998-09-24 2000-04-10 Algos Pharmaceutical Corporation Method for reducing nicotine dependency
DE69930552T2 (de) * 1998-12-16 2006-11-30 University Of South Florida, Tampa Exo-s-mecamylamin-formulierung und ihre verwendung in behandlungen
US6538010B1 (en) * 2000-11-08 2003-03-25 Research Triangle Institute Compounds and methods for promoting smoking cessation
US6780871B2 (en) * 2001-01-29 2004-08-24 Albany Medical College Methods and compositions for treating addiction disorders
US6582737B2 (en) * 2001-09-25 2003-06-24 Peirce Management, Llc Pharmaceutical composition containing two active ingredients for smoking cessation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP2086541A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2830601A4 (fr) * 2012-03-27 2015-09-23 Albany Medical College Blocage de la reprise de l'usage de drogues induite par un signal
CN103776928A (zh) * 2014-01-13 2014-05-07 红云红河烟草(集团)有限责任公司 一种检测尿液中3-羟基可替宁的方法

Also Published As

Publication number Publication date
CN101522193A (zh) 2009-09-02
WO2008045817A3 (fr) 2008-10-09
US20100040679A1 (en) 2010-02-18
EP2086541A2 (fr) 2009-08-12
CL2007002903A1 (es) 2008-04-18
JP2010505960A (ja) 2010-02-25
BRPI0719260A2 (pt) 2014-04-29
CA2676133A1 (fr) 2008-04-17
EA200970369A1 (ru) 2009-08-28
AR063148A1 (es) 2008-12-30
WO2008045817A8 (fr) 2009-05-07
EP2086541A4 (fr) 2011-06-22
MX2009003845A (es) 2009-04-23
AU2007307859A1 (en) 2008-04-17

Similar Documents

Publication Publication Date Title
US20100040679A1 (en) Compositions for Reducing Nicotine Withdrawal Symptoms and/or Tobacco Usage
US8940772B2 (en) Nicotine lozenge composition
AU2020273281B2 (en) Therapeutic uses of ibogaine and related compounds
HU206042B (en) Process for producing pharmaceutical compositions comprising indole-3-carboxylic acid-endo-8-methyl-8-azabicyclo/3.2.1./oct-3-yl ester and/or 1,2,3-9-tetrahydro-9-methyl-3-(2-methyl-1h-imidazol-1-yl)-methyl-4h-carbazol-4-one, with an activity preventing or reducing opiate-, alcohol- and nicotine-dependence
JP2010523587A (ja) 治療処置の副作用の低減のための方法および組成物
KR20080097443A (ko) 덱스트로메토판 및 퀴니딘을 포함하는, 우울, 불안 및 신경퇴행성 장애 치료용 약제학적 조성물
AU2020267217B2 (en) Therapeutic methods employing noribogaine and related compounds
JP5712452B2 (ja) 診断された呼吸疾患を有する患者もしくは診断未確定の呼吸疾患を有する患者におけるオピオイド鎮痛薬の投与に関連する危険性を減少するための方法および組成
US5414005A (en) Methods and articles of manufacture for the treatment of nicotine withdrawal and as an aid in smoking cessation
JPH02209808A (ja) 物質嗜癖の治療法
WO1995011679A1 (fr) Utilisation de la lobeline dans le traitement de symptomes de sevrage de nicotine
JP2000515548A (ja) ニコチン禁断症状を処置する方法
AU2013219211B2 (en) Nicotine lozenge compositions
TW574037B (en) Nicotine addiction treatment
Tjokroprawiro Review Article and Clinical Experience: VARENICLINE (CHAMPIX®): A BREAKTHROUGH FOR SMOKING CESSATION TREATMENT (An [alpha] 4 [beta] 2 Nicotinic Acethylcholine Receptor Partial Agonist)
Das et al. Nicotine Addiction–Quitting for Good
Climko Anticholinergics and Other Medicines

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780037669.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07843960

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007307859

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2040/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 12444208

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/003845

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2009532516

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2676133

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007843960

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007307859

Country of ref document: AU

Date of ref document: 20071008

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200970369

Country of ref document: EA

ENP Entry into the national phase

Ref document number: PI0719260

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090407